日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants

KCL-286(一种用于治疗脊髓损伤的新型维甲酸受体β激动剂)在男性健康受试者中的1期安全性、耐受性、药代动力学和药效学结果

Goncalves, Maria B; Mant, Tim; Täubel, Jörg; Clarke, Earl; Hassanin, Hana; Bendel, Daryl; Fok, Henry; Posner, John; Holmes, Jane; Mander, Adrian P; Corcoran, Jonathan P T

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort

利用研究性siRNA疗法fitusiran靶向治疗A型或B型血友病中的抗凝血酶——1期抑制剂队列研究结果

Pasi, K John; Lissitchkov, Toshko; Mamonov, Vasily; Mant, Tim; Timofeeva, Margarita; Bagot, Catherine; Chowdary, Pratima; Georgiev, Pencho; Gercheva-Kyuchukova, Liana; Madigan, Kate; Van Nguyen, Huy; Yu, Qifeng; Mei, Baisong; Benson, Craig C; Ragni, Margaret V

Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants

在健康受试者中评估新型整合素αvβ6抑制剂GSK3008348的安全性、耐受性和药代动力学

Maden, Charlotte H; Fairman, David; Chalker, Michelle; Costa, Maria J; Fahy, William A; Garman, Nadia; Lukey, Pauline T; Mant, Tim; Parry, Simon; Simpson, Juliet K; Slack, Robert J; Kendrick, Stuart; Marshall, Richard P

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.

在健康受试者中,阿达木单抗生物类似药(M923)与阿达木单抗(Humira)具有药代动力学等效性、可比安全性和免疫原性

Hillson Jan, Mant Tim, Rosano Molly, Huntenburg Carolyn, Alai-Safar Mehrshid, Darne Siddhesh, Palmer Donna, Pavlova Borislava G, Doralt Jennifer, Reeve Russell, Goel Niti, Weilert Doris, Rhyne Paul W, Chance Kamali, Caminis John, Roach James, Ganguly Tanmoy

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects

在健康受试者中比较阿达木单抗生物类似药 MSB11022 与 Humira® 的药代动力学、安全性和免疫原性

Hyland, Elizabeth; Mant, Tim; Vlachos, Pantelis; Attkins, Neil; Ullmann, Martin; Roy, Sanjeev; Wagner, Volker

Is there a role of synovial biopsy in drug development?

滑膜活检在药物研发中发挥什么作用?

Filkova, Maria; Cope, Andrew; Mant, Tim; Galloway, James

Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies

CYP3A4抑制剂酮康唑和维拉帕米以及CYP3A4诱导剂利福平对福斯他替尼药代动力学参数的影响:体外和I期临床研究结果

Martin, Paul; Gillen, Michael; Millson, David; Oliver, Stuart; Brealey, Clive; Grossbard, Elliott B; Baluom, Muhammad; Lau, David; Sweeny, David; Mant, Tim; Craven, Kelli

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

用于预防和按需治疗重型血友病A的聚乙二醇化全长重组凝血因子VIII

Konkle, Barbara A; Stasyshyn, Oleksandra; Chowdary, Pratima; Bevan, David H; Mant, Tim; Shima, Midori; Engl, Werner; Dyck-Jones, Jacqueline; Fuerlinger, Monika; Patrone, Lisa; Ewenstein, Bruce; Abbuehl, Brigitt

Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects

在两项针对健康志愿者和膝骨关节炎患者的 I 期研究中,评估了人源抗神经生长因子单克隆抗体 AMG 403 的安全性、耐受性、药代动力学和疗效。

Gow, Jason M; Tsuji, Wayne H; Williams, Gary J; Mytych, Daniel; Sciberras, David; Searle, Shawn L; Mant, Tim; Gibbs, John P

Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection

在健康志愿者和抑郁症患者中评估 AMPA 调节剂 Org 26576 的最大耐受剂量:支持 II 期剂量选择的桥接研究的总结和方法分析

Nations, Kari R; Bursi, Roberta; Dogterom, Peter; Ereshefsky, Larry; Gertsik, Lev; Mant, Tim; Schipper, Jacques